These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25052566)

  • 1. Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects.
    Dressler D; Tacik P; Saberi FA
    J Neural Transm (Vienna); 2015 Feb; 122(2):297-300. PubMed ID: 25052566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).
    Dressler D; Tacik P; Adib Saberi F
    J Neural Transm (Vienna); 2014 Jan; 121(1):29-31. PubMed ID: 23913131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.
    Moll M; Rosenthal D; Hefter H
    Parkinsonism Relat Disord; 2018 Dec; 57():63-67. PubMed ID: 30150129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Initial experiences with clinical use of botulinum toxin type B].
    Dressler D; Benecke R
    Nervenarzt; 2002 Feb; 73(2):194-8. PubMed ID: 11975099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.
    Dressler D; Benecke R
    Eur Neurol; 2003; 49(1):34-8. PubMed ID: 12464716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Botox and Xeomin for axillar hyperhidrosis.
    Dressler D
    J Neural Transm (Vienna); 2010 Mar; 117(3):317-9. PubMed ID: 20143241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical dystonia: factors deteriorating patient satisfaction of long-term treatment with botulinum toxin.
    Marciniec M; Szczepańska-Szerej A; Rejdak K
    Neurol Res; 2020 Nov; 42(11):987-991. PubMed ID: 32693754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin therapy for cervical dystonia.
    Jankovic J
    Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
    Dressler D; Kupsch A; Seitzinger A; Paus S
    Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-induced failure of botulinum toxin type B therapy in de novo patients.
    Dressler D; Bigalke H
    Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
    Marion MH; Humberstone M; Grunewald R; Wimalaratna S
    Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.
    Kollewe K; Mohammadi B; Köhler S; Pickenbrock H; Dengler R; Dressler D
    J Neural Transm (Vienna); 2015 Mar; 122(3):427-31. PubMed ID: 25059456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia.
    Münchau A; Palmer JD; Dressler D; O'Sullivan JD; Tsang KL; Jahanshahi M; Quinn NP; Lees AJ; Bhatia KP
    Brain; 2001 Apr; 124(Pt 4):769-83. PubMed ID: 11287376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.
    Greene PE; Fahn S
    Mov Disord; 1993 Oct; 8(4):479-83. PubMed ID: 8232357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation.
    Racette BA; McGee-Minnich L; Perlmutter JS
    Clin Neuropharmacol; 1999; 22(6):337-9. PubMed ID: 10626093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysphagia in cervical dystonia patients receiving optimised botulinum toxin therapy: a single-center retrospective cohort study.
    Kutschenko A; Klietz M; Paracka L; Kollewe K; Schulte-Sutum A; Janssen T; Schrader C; Wegner F; Dressler D
    J Neural Transm (Vienna); 2020 Aug; 127(8):1161-1165. PubMed ID: 32588245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.